Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85


Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells.

Kazokaitė J, Niemans R, Dudutienė V, Becker HM, Leitāns J, Zubrienė A, Baranauskienė L, Gondi G, Zeidler R, Matulienė J, Tārs K, Yaromina A, Lambin P, Dubois LJ, Matulis D.

Oncotarget. 2018 Jun 1;9(42):26800-26816. doi: 10.18632/oncotarget.25508. eCollection 2018 Jun 1.


Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes.

Aspatwar A, Becker HM, Parvathaneni NK, Hammaren M, Svorjova A, Barker H, Supuran CT, Dubois L, Lambin P, Parikka M, Parkkila S, Winum JY.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1064-1073. doi: 10.1080/14756366.2018.1482285.


Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.

Ureba A, Lindblom E, Dasu A, Uhrdin J, Even AJG, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I.

Acta Oncol. 2018 Apr;57(4):485-490. doi: 10.1080/0284186X.2017.1400177. Epub 2017 Nov 16.


Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer.

Even AJG, Reymen B, La Fontaine MD, Das M, Mottaghy FM, Belderbos JSA, De Ruysscher D, Lambin P, van Elmpt W.

Radiother Oncol. 2017 Dec;125(3):379-384. doi: 10.1016/j.radonc.2017.09.041. Epub 2017 Nov 6.


Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.

Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O'Connor JPB, Faivre-Finn C.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx160. Review.


Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.

Even AJG, Reymen B, La Fontaine MD, Das M, Jochems A, Mottaghy FM, Belderbos JSA, De Ruysscher D, Lambin P, van Elmpt W.

Acta Oncol. 2017 Nov;56(11):1591-1596. doi: 10.1080/0284186X.2017.1349332. Epub 2017 Aug 25.


Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review.

Peerlings J, Van De Voorde L, Mitea C, Larue R, Yaromina A, Sandeleanu S, Spiegelberg L, Dubois L, Lambin P, Mottaghy FM.

Methods. 2017 Nov 1;130:51-62. doi: 10.1016/j.ymeth.2017.07.002. Epub 2017 Jul 10. Review.


A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume".

Yaromina A, Granzier M, Biemans R, Lieuwes N, van Elmpt W, Shakirin G, Dubois L, Lambin P.

Radiother Oncol. 2017 Sep;124(3):513-520. doi: 10.1016/j.radonc.2017.04.020. Epub 2017 May 11.


Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.

Lindblom E, Dasu A, Uhrdin J, Even A, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I.

Acta Oncol. 2017 Jun;56(6):819-825. doi: 10.1080/0284186X.2017.1293289. Epub 2017 Mar 2.


Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer.

Verwer EE, Zegers CM, van Elmpt W, Wierts R, Windhorst AD, Mottaghy FM, Lambin P, Boellaard R.

EJNMMI Phys. 2016 Dec;3(1):30. Epub 2016 Dec 12.


New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.

van Kuijk SJA, Parvathaneni NK, Niemans R, van Gisbergen MW, Carta F, Vullo D, Pastorekova S, Yaromina A, Supuran CT, Dubois LJ, Winum JY, Lambin P.

Eur J Med Chem. 2017 Feb 15;127:691-702. doi: 10.1016/j.ejmech.2016.10.037. Epub 2016 Oct 19.


[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.

de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):8-16. Epub 2016 Sep 6.


A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.

Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P.

BMC Cancer. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z.


The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.

van Kuijk SJ, Gieling RG, Niemans R, Lieuwes NG, Biemans R, Telfer BA, Haenen GR, Yaromina A, Lambin P, Dubois LJ, Williams KJ.

PLoS One. 2016 Aug 11;11(8):e0161040. doi: 10.1371/journal.pone.0161040. eCollection 2016.


Synthesis and in Vivo Biological Evaluation of (68)Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography.

Sneddon D, Niemans R, Bauwens M, Yaromina A, van Kuijk SJ, Lieuwes NG, Biemans R, Pooters I, Pellegrini PA, Lengkeek NA, Greguric I, Tonissen KF, Supuran CT, Lambin P, Dubois L, Poulsen SA.

J Med Chem. 2016 Jul 14;59(13):6431-43. doi: 10.1021/acs.jmedchem.6b00623. Epub 2016 Jun 29.


Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer.

Zegers CM, Hoebers FJ, van Elmpt W, Bons JA, Öllers MC, Troost EG, Eekers D, Balmaekers L, Arts-Pechtold M, Mottaghy FM, Lambin P.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2139-2146. Epub 2016 Jun 1.


Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.

Carvalho S, Troost EG, Bons J, Menheere P, Lambin P, Oberije C.

Radiother Oncol. 2016 Jun;119(3):487-94. doi: 10.1016/j.radonc.2016.04.024. Epub 2016 Apr 29.


Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.

van Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ.

Front Oncol. 2016 Mar 29;6:69. doi: 10.3389/fonc.2016.00069. eCollection 2016. Review.


A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy.

Walsh S, Roelofs E, Kuess P, Lambin P, Jones B, Georg D, Verhaegen F.

Med Phys. 2016 Feb;43(2):734-47. doi: 10.1118/1.4939260.


Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.

van Elmpt W, Zegers CM, Reymen B, Even AJ, Dingemans AM, Oellers M, Wildberger JE, Mottaghy FM, Das M, Troost EG, Lambin P.

Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):240-8. doi: 10.1007/s00259-015-3169-4. Epub 2015 Sep 4.

Supplemental Content

Loading ...
Support Center